Video

PARP Combination Therapies in Ovarian Cancer

Transcript:

Bradley J. Monk, MD, FACS, FACOG: We want more, and we want to combine things. Leslie, I know one of the things that you’re passionate about is adding checkpoint inhibitors to PARP inhibitors. There’s a study called TOPACIO. Can you tell us about TOPACIO?

Leslie M. Randall, MD, MAS: Yes. TOPACIO takes this to the next level. This is PARP inhibitor in addition to pembrolizumab, a PD-1 inhibitor. The PARP inhibitor is niraparib. At the current time, they’re looking at both breast cancer patients and platinum-resistant recurrent ovarian cancer patients.

TOPACIO was presented at the 2018 Society for Gynecologic Oncology Annual Meeting. The combination does, in fact, work. And interestingly, there was a signal not only in the biomarker-positive groups, in adding your PD-L1 biomarker to that molecular signature with HRD, but there was also a signal in those who were biomarker-negative.

Bradley J. Monk, MD, FACS, FACOG: What’s the response rate?

Leslie M. Randall, MD, MAS: The overall response rate is about 12% to 20%, but this needs to be further studied, especially in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG: The study is ongoing.

Leslie M. Randall, MD, MAS: The study is ongoing, and this needs to be expanded to have a larger ovarian cancer cohort. But, it’s certainly worthy of further study.

Bradley J. Monk, MD, FACS, FACOG: Here’s what people say, and I know that you’re going to jump on me. In the MEDIOLA trial, which is olaparib/durvalumab, the rate is 70%. When you tell me that this is 20% to 25%, that’s half.

Leslie M. Randall, MD, MAS: I think you have to look at the differences in the populations. MEDIOLA looked at a platinum-sensitive population. We’ve been talking about how our PARP inhibitors are effective in these patients. With the addition of durvalumab, I’m not sure.

Bradley J. Monk, MD, FACS, FACOG: In a biomarker-positive group.

Leslie M. Randall, MD, MAS: Exactly. TOPACIO is a completely different approach in the resistant population, which is an unmet medical need.

Bradley J. Monk, MD, FACS, FACOG: Tom, I know you’re passionate about adding PARP inhibitors with an antiangiogenic. She says to use PARP with immuno-oncology. Maybe we can combine a PARP and antiangiogenic? What do you think?

Thomas Herzog, MD: I think it’s interesting. There’s preclinical data in all of these areas with these combinations of PARP inhibitors with antiangiogenics and PARP inhibitors with I-O therapies. The I-O story is interesting. You may change the sensitivity by creating these neoantigens, increasing the mutational load, and then coming in and hitting it with the I-O. There’s a study known as ANANOVA that’s looking at a PARP inhibitor with niraparib plus or minus bevacizumab. It’s a phase I, phase II program. We should have data early next year. It’s really an interesting strategy. You’re basically sparing the patient of platinum in a platinum-sensitive setting, which is really an interesting strategy. And, frankly, the response rates and the duration of responses that we’re seeing make it a strategy that should be looked at.

Bradley J. Monk, MD, FACS, FACOG: And that’s being expanded in the OVARIO study, right?

Thomas Herzog, MD: Right. OVARIO is niraparib and plus or minus bevacizumab in the platinum-sensitive maintenance setting.

Bradley J. Monk, MD, FACS, FACOG: That’s great.

Transcript Edited for Clarity

Related Videos
Kimberly Cannavale, MPH
Jean-Marc Classe, MD, PhD, Nantes Université
Emil Lou, MD, PhD, FACP
Amma Asare, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD
Vaidehi Mujumdar, MD
Erin Crane, MD, MPH
Núria Agustí Garcia, MD
Yang Yang Hartwich, PhD